Novartis: Ups and downs result in final upgrade of FV by CHF2 and much better sentiment

BUY, Fair Value CHF70 vs. CHF68 (+12%)

News published on January Thursday 24, 2013
Share on

We are upgrading our FV by CHF2 on Novartis, o/w CHF1 is the introduction of RLX030 into our forecasts for the first time with a probability-adjusted peak sales of USD1.4bn and the other CHF1 the halving of our stock-specific risk premium which reflected the gap in shareholder friendliness compared to peers (disclosure, guidance, share buy-backs, communication) that has already improved and is likely to continue to do so with changes at the Board level.

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities